Sally Alrabaa, MD

Biographical Sketch

Dr. Alrabaa is an Assistant Professor in the Division of Infectious Disease and International Medicine at the University of South Florida. Dr. Alrabaa received her medical degree from the University of Kartoum in Sudan, completed her internal medicine residency at Saint Vincent Hospital (affiliated with new York Medical College), and completed her infectious disease fellowship at the University of South Florida.

Dr. Alrabaa is also affiliated with the Florida Department of Health - Hillsborough County as a supervising attending physician in the Specialty Care Clinic and as an investigator in the Clinical Research Unit.

Areas of Expertise

Infections in transplant recipients, healthcare associated infections, travel related infections, and HIV/AIDS.

Current Research

Alrabaa S. Merck MK 3415-002. A pilot, randomized, controlled study to evaluate the safety and efficacy of antitoxin A and B in Clostridium difficile associated diarrhea. Tampa, FL, 2012 - present

Alrabaa S, Greene J. Interferon gamma the treatment of disseminated mycobacterium abscesses infection in leukemic patients. H. Lee Moffitt Cancer Center, Tampa, 11/2010

Alrabaa S, Greene J. Alpha interferon in the treatment of RSV pneumonia in bone marrow transplant recipients; improved morbidity and mortality. H. Lee Moffitt Cancer Center, Tampa, 1/2009 – 10/2009 [Abstract presented at IDSA Annual Meeting, 10/2009]

Alrabaa A, Greene J. Fluoroquinolone resistance among leukemic patients receiving fluoroquinolone prophylaxis; increased incidence but improved overall morbidity. H. Lee Moffitt Cancer Center, Tampa, 9/2008 – 12/2008 [Abstract presented at IDSA Annual Meeting, 10/2009]

Ongoing protocols (co-investigator):

Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK‑1439 Plus TRUVADA^™ Versus Efavirenz Plus TRUVADA^™ in Antiretroviral Treatment-Naïve, HIV-1 Infected Patients [MK-1439-007-07]

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults [GS-US-292-0104]

Quality of Life of HIV-Infected Patients Switched to Raltegravir versus other Antiretroviral Regimens  [Merck 96615]

A prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate whether EGRIFTA^® (tesamorelin for injection), 2 mg once daily SC, increases the risk of development or progression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes [EMR200147-500]

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

DAIDS-START Schering- P04875 (A673DL)  Strategical Timing of Antiretroviral Therapy. CPCRA START 

Efficacy and Safety of Vicriviroc in HIV-Infected Treatment Naive Subjects (Funded: 239,173) 2009-Present

Merck-IISP 33107 (A673CG) A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir versus NRTIs as a Backbone in HIV-Infected Patients Switched from a Stable Boosted PI Regimen (Funded: 74,561)

Gilead (GS-US-236-0102) A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Gilead (GS-US-236-0103) A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir- Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Gilead (GS-US-236-0124) A Phase 3, Randomized, Double Blinded Study to Evaluate the Safety and Efficacy of GS-9350 Boosted Atazanavir Versus Ritonavir=Boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Tibotec (TMC278-209) A Phase III, Randomized, Double-Blind Study of TMC278 25 mg once daily in Combination with a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive HIV-1 Infected Subjects

Gilead (GS-US-183-0130) A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults

Publications/Presentations

Alrabaa S, Nguyen P, Sanderson R, Baluch A, Sandin R, Kelker D, Karlapalem C, Thompson P, Sams K, Martin S, Montero J, Greene J. Early identification and control of carbapenemase-producing Klebsiella penumoniae, originating from contaminated endoscopic equipment. American Journal of Infection Control (AJIC), 2013, in press

Pham T, Alrabaa S, Somboonwit C, Hung L, Montero J. The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia. J Int Assoc Physicians AIDS Care (Chic). 2011 Jan-Feb; 10(1):54-6. University of South Florida, College of Medicine, Tampa, FL, USA. Available online.

Alrabaa S, Greene J. Alpha interferon in the treatment of RSV pneumonia in bone marrow transplant recipients, improved morbidity and mortality. Presented at: Infectious Disease Society of America (IDSA) Annual Meeting, Oct. 2009, Philadelphia, PA

Alrabaa S, Greene J. Fluoroquinolone resistance among leukemic patients receiving fluoroquinolone prophylaxis, increased incidence but improved overall morbidity, IDSA Annual Meeting, Oct 2009, Philadelphia, PA

Wills T, Sinnott JT, Alrabaa S. Viral Hemorrhagic Fevers. APIC Text of Infection Control and Epidemiology, 3rd ed. Association for Professionals in Infection Control and Applied Epidemiology Principles and Practice (APIC). Washington, 2009

Dr. Alrabaa's CV